907 results on '"Stage III Non-Small Cell Lung Cancer"'
Search Results
2. PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC (PACCELIO)
3. Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
4. Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
5. Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
6. Treatment patterns and clinical outcomes of resectable clinical stage III non‐small cell lung cancer in a Japanese real‐world setting: Surgery cohort analysis of the SOLUTION study.
7. Treatment patterns and clinical outcomes of resectable clinical stage III non‐small cell lung cancer in a Japanese real‐world setting: Surgery cohort analysis of the SOLUTION study
8. Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
9. Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)
10. Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer (ARTIA-Lung)
11. A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
12. Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
13. Efficacy and safety of definitive chemoradiotherapy with or without induction immune checkpoint inhibitors in patients with stage III non-small cell lung cancer.
14. Improved overall survival for Stage III NSCLC patients treated with curative-intended therapy from 2010 to 2018–a cohort study in Denmark.
15. Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer.
16. Treatment of Stage III Non-small Cell Lung Cancer
17. Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study
18. Tumor to liver maximum standardized uptake value ratio of FDG-PET/CT parameters predicts tumor treatment response and survival of stage III non-small cell lung cancer
19. Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
20. Differences between professionals in treatment planning for patients with stage III lung cancer using treatment-planning QA software.
21. Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study.
22. Tumor to liver maximum standardized uptake value ratio of FDG-PET/CT parameters predicts tumor treatment response and survival of stage III non-small cell lung cancer.
23. Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC
24. Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia"
25. Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC
26. Expert consensus on treatment for stage III non‐small cell lung cancer
27. Interpretation of expert consensus on treatment for stage III non‐small cell lung cancer
28. Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
29. Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
30. Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?
31. Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial
32. Cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer.
33. Long‐term outcomes of high‐dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III nonsmall‐cell lung cancer
34. A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable Non-Small Cell Lung Cancer
35. Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?
36. Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017.
37. Deciphering the clinical features of heterogeneous stage III non-small cell lung cancer in Japanese real-world clinical practice: Expanded cohort of the SOLUTION study.
38. Relevance of multi‑disciplinary team approach in diagnosis and management of Stage III NSCLC.
39. Nationwide Real-Life Safety and Treatment Exposure Data on Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III, Locally Advanced, Non-small Cell Lung Cancer: Analysis of Patients Enrolled in the French Early Access Program.
40. Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe
41. An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study
42. Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
43. A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable Non-Small Cell Lung Cancer.
44. Long‐term outcomes of high‐dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III nonsmall‐cell lung cancer.
45. Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non‐small cell lung cancer: Results of a single‐arm prospective cohort study
46. Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer
47. Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy (IDEAL-VMAT)
48. Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC (NVALT11)
49. MRI Optimization Study in Stage III NSCLC
50. Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.